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ABSTRACT Peptides from different regions of the polio-
virus type 1 capsid protein VP1 were synthesized. Antibodies
raised against these peptides in rabbits and rats recognized the
cognate peptides and denatured VP1. Peptides from four re-
gions ofVP1 generated antisera with neutralizing titers specifi-
cally against poliovirus type 1. Antisera against all other re-
gions of VP1 failed to neutralize virus infectivity, although
some of the antisera clearly bound to native virions. Thus, the
neutralizing determinants on VP1 reside in specific noncontig-
uous regions of the protein and can be defined by specific pep-
tides from these regions.
An animal's immunologic response against a viral antigen is
a composite of many antibodies, of which those that neutral-
ize infectivity comprise a specific subset. Because the neu-
tralizing response plays a major protective role, the charac-
terization of the antibodies, their specificities, and their
functional role in the neutralization process is crucial to an
understanding of the pathobiology of a virus. In addition, the
definition of neutralizing epitopes should help in the under-
standing of initial virus-cell interactions.
It previously has been shown that major neutralizing de-
terminants are found on the poliovirus type 1 capsid protein
designated VP1. The isolated, denatured VP1 is capable of
inducing virion-neutralizing antibodies in rats (1) and rabbits
(2). VP1 is immunoprecipitated by a neutralizing anti-virion
monoclonal antibody, C-3 (3). In addition, using this mono-
clonal antibody, Wychowski et al. (4) have shown that a neu-
tralization epitope was located within the region of amino
acid residues 90-104 of VP1. Analysis of virion mutants that
are resistant to neutralizing anti-virion monoclonal antibod-
ies showed that a major neutralizing determinant for poliovi-
rus type 3 was localized within VP1 in the region of amino
acid residues 96-106 (5, 6). Characterization of a large set of
neutralizing anti-virion monoclonal antibodies against polio-
virus type 1 also indicated that the amino acid region 94-104
of VP1 contained a neutralizing determinant (7). In addition,
an additional amino acid region (residues 70-80) was recog-
nized by some monoclonal antibodies (7). Thus, it appears
that VP1 potentially possesses several neutralizing determi-
nants.
To further characterize the neutralization response against
VP1 and to structurally characterize the neutralization epi-
topes, we derived a partial antigenic map of VP1, using anti-
sera made against synthetic peptides from different regions
throughout the VP1 protein. We report here that synthetic
peptides spanning four separate regions of the VP1 sequence
will induce neutralizing antibodies. These serotype-specific
antibodies recognize VP1 and the intact mature poliovirus
virion. The ability of these four regions to generate neutraliz-
ing antibodies is independent of the choice of immunizing
host.
METHODS
Synthesis and Coupling of Peptides. The peptides were syn-
thesized by R. Houghten, with solid-phase methods using a
Beckman model 990B peptide synthesizer (8, 9). The pep-
tides were cleaved from the resin and passed through a Seph-
adex G-25 sizing column. The void volume was collected,
and the amino acid composition of the peptide sample was
determined. In the rare case when the amino acid composi-
tion varied more than 5% from the theoretically predicted
composition, the peptide sample was further purified by us-
ing high-pressure chromatographic techniques. In general,
the Sephadex G-25-purified peptides were used directly for
further studies.
Keyhole limpet hemacyanin (KLH; Calbiochem-Behring)
was used as the carrier protein in all coupling reactions. Two
peptides were not sufficiently soluble in any of the reaction
buffers tried and were injected into the animal as free, un-
coupled peptide. Two methods of coupling were used. Pep-
tides that contained cysteine were coupled by using m-malei-
midobenzoyl-N-hydroxysuccinimide ester (MBS) as de-
scribed by Liu et al. (10). Peptides that did not contain a
cysteine residue were coupled by using gluteraldehyde as de-
scribed by Baron and Baltimore (11).
Immunization of Animals. New Zealand White rabbits and
Lewis rats, 8 wk old (Charles River Breeding Laboratories),
were immunized with either KLH-coupled or free peptides.
The animals were injected intraperitoneally and intradermal-
ly with emulsions containing 100 ,ug of the coupled carrier
protein or of the free peptides. To equalize variability among
the individual animals, each peptide was injected into at least
two (usually three) rats and two rabbits. The emulsions were
made by mixing equal volumes of the protein sample and
complete Freund's adjuvant. After 3 wk, the initial injection
was followed by three or four booster injections 2 wk apart.
Each booster injection contained 100 ,4g of protein in a 50%
emulsion with incomplete Freund's adjuvant for rats or with
alum for rabbits. Animals were bled 8-10 days after each
booster injection, and antiserum was isolated. Antisera were
heated to 650C for 30 min before storage at -200C.
Slot-Blot Assays. The specificity of the antisera was exam-
ined by using a slot-blot assay. Peptide or protein samples
(0.5 ug/100 1.l) were bound to nitrocellulose filter strips pre-
soaked in phosphate-buffered saline by using a vacuum man-
ifold (Schleicher & Schuell). The air-dried filter was blocked
with blocking buffer [phosphate-buffered saline containing
3% bovine serum albumin (fraction V, Pentex, Kankakee,
IL)] at 371C for 90 min with shaking. At the end of the incu-
bation, the filter was incubated with the serum samples,
Abbreviations: KLH, keyhole limpet hemacyamin; pfu, plaque-
forming units.
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which had been diluted in blocking buffer. Peptide competi-
tion of serum samples was done by incubating the filter with
serum samples in the presence of peptide at 100 /Lg/ml. The
incubations were at 370C for 30 min. The filters were rinsed
briefly with blocking buffer and then washed three times
with a large excess of the same buffer at room temperature
for 15 min with shaking. For the rabbit antisera, the washed
filters were incubated with 125I-labeled Staphylococcus au-
reus protein A (1 jiCi/ml, New England Nuclear; 1 Ci = 37
GBq) in blocking buffer for 60 min at 370C with shaking. The
filters were washed three times with Triton buffer (blocking
buffer containing 1.0% Triton X-100) at room temperature
for 15-20 min each and then were air-dried. The filters were
autoradiographed (Kodak, XAR film) at -70'C with intensi-
fying screens (Lightning Plus, Dupont). For the rat antisera,
the filters were incubated with a second antibody, biotinylat-
ed-rabbit anti-rat IgG. The antibody complexes were visual-
ized by using an avidin-biotinylated alkaline phosphatase
complex by the methods of Costello et al. (12) and Leary et
al. (13).
Neutralization Titers. The titer of neutralizing antibody
present in the anti-peptide antisera was measured by a
plaque-reduction assay and a cytopathic-effect end-point in-
hibition assay. The plaque-reduction assay, with an input of
200 plaque-forming units (pfu) was as described (1). Titers
were given as the antiserum dilution that would diminish the
apparent titers by 50%. The ability of the antisera to com-
pletely neutralize virus infectivity and consequently its lytic
cytopathic effect was measured by incubating serial dilu-
tions (1:2) of antiserum in phosphate-buffered saline with
1000 pfu of poliovirus in a final volume of 50 1.l for 2 hr at
250C and then overnight at 40C. The virus-antiserum sample
was allowed to adsorb to CV-1 cells plated in microtiter
plates (104 cells per well) for 30 min at 370C. The inoculum
was removed, and the wells were overlayed with fresh medi-
um (Dulbecco's modified Eagle's medium containing 5% fe-
tal calf serum and 0.01 M Hepes, pH 7.2) and incubated at
37°C for 24 hr (polio type 1, Mahoney) or for 48 hr (polio type
2, Lansing). All assays were carried out in duplicate and
were visualized by staining with crystal violet. Titers were
given as the first dilution of antiserum where the cells were
completely lysed by the virus.
All other methods were as previously described (1).
RESULTS
The capsid protein of poliovirus type 1 (Mahoney strain),
VP1, is 302 amino acids long, and its complete amino acid
sequence is known from its nucleotide sequence (14, 15). A
series of peptides were selected to represent regions that
map throughout the entire VP1 sequence (Fig. 1). Among the
peptides selected were ones with high hydrophilicity indices
or with significant sequence variability between strains. In
addition, after comparison of the chemical properties of the
VP1 peptide regions for all known picornavirus strains-in-
cluding the known VP1 sequences for different strains of
foot and mouth disease virus (FMDV) (unpublished data)-
several peptides were selected because they might span re-
gions that were analogous to peptide sequences of FMDV























FIG. 2. Antigen specificities of the anti-peptide antisera. The
antigenic analysis of one anti-peptide antisera (anti-peptide 1) is
shown. Peptides 1-13b, KLH, VP1, VP2, and VP3 were bound to a
nitrocellulose filter and subsequently incubated with rat antisera.
The antibody complexes were visualized by using a biotinylated rab-
bit anti-rat IgG-avidin-biotinylated alkaline phosphatase sandwich.
The filters were incubated with normal rat serum (lane 1), anti-pep-
tide 1 antiserum (lane 2), anti-peptide 1 antiserum in the presence of
peptide 1 (lane 3), anti-peptide 1 antiserum in the presence of pep-
tide 6 (lane 4), and anti-peptide 6 antiserum (lane 5). The anti-pep-
tide 1 antiserum was raised against peptide 1 coupled to KLH. The
anti-peptide 6 antiserum was raised against uncoupled peptide 6.
that induced neutralizing antibodies (16, 17). These chemi-
cally synthesized peptides were coupled to KLH and inject-
ed into rats and rabbits. Antisera were obtained from the
immunized animals 1 week after the last booster.
Characterization of Anti-Peptide Antisera. The antigen
specificities of the various anti-peptide antisera were qualita-
tively assayed by using slot blots (Figs. 2 and 3). Every anti-
serum reacted with its cognate peptide and, in cases when
the peptides were coupled to the carrier protein, with KLH
(Fig. 2, lanes 2 and 5; Fig. 3 A and B; Table 1). The antisera
were quite specific. With the exception of the antisera to
peptides 3, 12a, 12b, and 8, each antiserum recognized solely
its cognate peptide. The recognition by each antiserum was
specifically blocked in competition by the cognate peptide
0 20 60 100
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FIG. 1. Location of the synthetic peptides within the VP1 sequence. The peptide numbers denote the locations of the synthetic peptides
along the linear VP1 amino acid sequence for the type 1, Mahoney strain; the amino acid sequence was determined from the nucleotide
sequence (14, 15). The amino acid residues are numbered with the NH2-terminal glycine at position 1 and residue 302 at the COOH terminus.
The exact amino acid residues spanning each peptide is specified in Table 1. *, Peptides that induce neutralizing responses; n, peptides whose
antisera will recognize and bind virions but do not neutralize (see text).
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FIG. 3. Peptide recognition by anti-peptide and anti-VP1 antise-
ra. The crossreactivity of anti-VP1 and anti-peptide 8 antisera with
the different VP1 peptides was tested by using slot blots. The pep-
tides were spotted according to the key given in the upper right-hand
corner of this figure. The filters were incubated with anti-peptide 8
(A), anti-peptide 2 (B), and anti-VP1 (C) rat antisera. The antibody
complexes were visualized as described.
and not by any of the other VP1 peptides (Fig. 2, lanes 3 and
4). As would be expected, antiserum to peptide 3 recognized
not only its cognate peptide, but it also recognized other pep-
tides that overlap the peptide 3 amino acid sequence, pep-
tides 12a, 12b, 13a, and 13b (Table 1). Similarly, antisera ob-
tained against 12a and 12b strongly recognized peptides 12a
and 12b and to a lesser extent peptides 3, 13a, and 13b. Al-
though antiserum to peptide 8 showed high reactivity against
8, it appeared to bind weakly to peptides 3, 12a, 12b, 13a,
13b, and 7 (Fig. 3A). Incubation of the antisera with an ex-
cess of peptide 8 in solution effectively blocked recognition
of all of the peptides except peptide 7 (data not shown). This
indicates that the reactivity of the antiserum of anti-peptide 8
with peptides 3, 12a, 12b, 13a, and 13b is specific and that
the recognition of peptide 7 is probably nonspecific. This
spectrum of recognition by anti-peptide 8 antiserum with
peptides 3, 12a, 12b, 13a, and 13b was seen with both the rat
and the rabbit antisera, suggesting that the cross-reactivity
was characteristic of the amino acid sequence represented in
peptide 8.
All of the anti-peptide antisera reacted with isolated dena-
tured VP1. Sera directed against peptides 7, 8, and 2 consis-
tently showed much weaker reactivity against the denatured
VP1 when compared with the other anti-peptide antisera.
None of the anti-peptide antisera recognized isolated, dena-
tured VP2 or VP3, as might be expected from their se-
quences.
The ability of sera raised against VP1 to react with pep-
tides was also assessed (Fig. 3C). Peptides 5, 7, 8, and 9 were
specifically recognized, and these reactions were competi-
tively blocked by the addition of isolated VP1.
Neutralization Activity of Anti-Peptide Antisera. The ability
of the anti-peptide antisera to neutralize poliovirus infectiv-
ity was assayed by (i) 50% reduction of titer upon exposure
of 200 poliovirus pfu to the serum or (ii) total inhibition of the
viral cytopathic effect and cell lysis induced by 1000 pfu by
using various dilutions of sera in an end-point titration in liq-
uid culture (Table 2). Antisera against several peptides (2, 6,
12a, 12b, 8, 11a, and lib) showed similar neutralizing titers
in both the cytopathic-effect and plaque-reduction assays.
These peptides map to four separate regions of VP1, amino
acids 61-80, 95-109, 182-201, and 222-264. The neutralizing
titers varied for the different peptides, and they were uni-
formly low compared to the titers of anti-virion antisera.
Several of the anti-peptide antisera (against peptides 4, 7,
and 10) showed no neutralizing activity in either assay (Table
2). These antisera were directed against peptides from three
different regions of VP1. Thus, peptides from specific re-
gions in VP1 will induce antibodies that recognize the pep-
tide as well as denatured VP1 but fail to neutralize the infec-
tivity of the virus. Consistent with these observations, each
of these anti-peptide antisera failed to precipitate labeled vi-
rions from solution.
Four anti-peptide antisera (against peptide 1, 3, 5, and 9)
consistently showed no neutralizing titers in the end-point
titration assay, even at undiluted serum concentrations, but
showed measurable titers in the plaque-reduction assay.
These sera were raised against peptides from amino acid re-
Table 1. Preparation and specificity of antisera
Antiserum preparation Antiserum specificity
Coupling Cognate
Peptide Amino acid method/carrier peptide Other peptide Reaction with:
no. no. protein reactivity reactivities KLH VP1 VP2 VP3 Virions
1 24-40 MBS/KLH + + + - - +
2 61-80 MBS/KLH + + + - - +
3 86-103 MBS/KLH + 12a,b; 13a,b + + - - +
4 121-141 Free + - +
5 161-181 Gluter/KLH + + + - - +
6 182-201 Free + - + - - +
7 202-221 MBS/KLH + + + - - -
8 244-264 MBS/KLH + 12a,b; 13a,b; 3; 7 + + - - +
9 270-287 Free + - + - - +
10 286-302 MBS/KLH + + + - - -
11a 222-241 Gluter/KLH + + + - - +
11b 222-241 MBS/KLH + + + - - +
12a 100-109 MBS/KLH + 3; 12b; 13a,b + + - - +
12b 91-109 MBS/KLH + 3; 12a; 13a,b + + - - +
13a 100-109
13b 91-109
Peptides 1-12b correspond to the sequence of poliovirus type 1 capsid protein, Mahoney strain; peptides 13a and 13b are derived from the
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Table 2. Neutralizing titers of anti-peptide antisera
Dilution giving Dilution preventing CE
Antisera. 50% PR against
against type 1 virus Type 1 virus Type 2 virus
peptide no. (rabbit) Rabbit Rat Rabbit
1 1:100 ND




6 1:150 1:200 1:150 1:5
7
- ND
8 1:10 1:20 1:25
9 1:10 ND
10 ND
11a 1:100* ND 1:80 1:5*
11b 1:100* ND 1:140 1:5*
12a 1:150* ND 1:100 1:10*
12b 1:50* ND 1:80 1:5*
ND, not determined; CE, cytopathic effect; PR, plaque reduction.
*Titers were determined using rat antisera.
gions 24-40, 86-103, 161-181, and 286-302 in VP1. This
group of antisera also will precipitate virions. These results
are best explained by aggregation of the virus particles by
the antibodies. The fact that specific regions on the virion
surface generate antibodies that bind to, but do not neutral-
ize, the virus indicates that the neutralization determinants
are specific sites on the virus and not a general, nonspecific
surface interference with virus infectivity.
Similar neutralizing titers were observed in antisera from
immunized rats as in rabbits (Table 2). The peptides that elic-
ited neutralizing antibodies in rats also elicited neutralizing
antibodies in rabbits. The relative titers for each peptide
were also similar between the two animal systems. Thus, for
these sequences, the ability of a peptide to induce the pro-
duction of neutralizing antibody is apparently a property of
the peptide sequence and is not a reflection of unusual im-
munological characteristics peculiar to the animal host sys-
tem chosen. Although the observed titers for the anti-peptide
antisera in both animal systems were extremely low com-
pared with those obtained for antisera against poliovirus viri-
ons, these anti-peptide titers were comparable to those mea-
sured for antiserum made against isolated, denatured VP1
protein (1). In addition, similar to the characteristics of the
anti-VP1 antiserum, antisera made against peptides from the
type 1 Mahoney strain VP1 sequence appear to neutralize
type 1 poliovirus (Mahoney strain) more effectively than
type 2 poliovirus (Lansing strain). Thus, the observed neu-
tralizing activity for both anti-VP1 and anti-peptide antisera
is apparently serotype specific, mimicking the characteris-
tics of the neutralizing anti-virion antisera.
DISCUSSION
We have demonstrated that peptides from four separate re-
gions of the poliovirus capsid protein VP1 can induce neu-
tralizing antibodies in two mammalian species. These anti-
bodies recognize and will bind to the cognate peptide, dena-
tured VP1, and native virions. Although the titers are
extremely low compared to the neutralizing titers of anti-vi-
rion antisera, the anti-peptide titers are comparable to those
observed with antisera to denatured VP1 (1) and are sero-
type specific. Peptides from other regions of VP1 will induce
antibodies that bind to virions but fail to completely block
the infectivity of virus. Finally, several peptides induce anti-
bodies that bind to the cognate peptide and denatured VP1
but fail both to bind to the native virus and to neutralize the
infectivity of poliovirus.
Comparison with Earlier Results. Our results agree with
and extend previous analyses of antigenic sites on the polio-
virion. By analyzing mutants that escape neutralization by
monoclonal antibodies, Minor et al. (5) suggested that amino
acids 96-106 of the type 3 VP1 protein should be a neutral-
ization site. (The analogous region from the type 1 VP1 is
contained in our peptide 12b.) Emini et al. (7) showed that
neutralizing monoclonal anti-type 1 antibodies would react
with regions defined by our peptides 12b and 2. They also
showed that a peptide consisting of amino acids 93-103
would elicit neutralizing antibodies. Using a series of dele-
tions, Wychowski et al. (4) also showed that recognition of
VP1 expressed in bacterial cells by the neutralizing anti-viri-
on monoclonal antibody C-3 resided within the region of
amino acid residues 90-104.
Our observation of neutralizing regions separate from
those defined previously was presaged by Kew and Nottay
(18), who indicated that other undefined neutralizing deter-
minants were present in VP1. They found that in Sabin type
1 isolates that had antigenically drifted after immunization of
healthy infants, there was no consistent correlation with nu-
cleotide sequence changes corresponding to amino acids 1-
125. Thus, these data implied the presence of neutralizing
determinants in the COOH-terminal half of the VP1 protein.
Our definition of two peptide regions from the COOH-termi-
nal half of VP1 that will elicit neutralizing antibodies is con-
sistent with these observations. Further analysis of the viral
epitopes will be necessary to determine whether these neu-
tralizing regions represent the complete set of neutralizing
determinants present in VP1 or whether additional sites ex-
ist.
A curious aspect of our results was that peptide 3 (amino
acids 86-103) generated antibodies that bound to virions but
did not neutralize the infectivity of the virus. The COOH-
terminus of this peptide overlapped into a region that was
demonstrated to be a neutralizing determinant (peptides 12a
and 12b; see Table 1), and Emini et al. (7) had shown that
only the amino acids from positions 93-103 were needed to
elicit a response. The lack of neutralizing activity by peptide
3 is therefore puzzling, but possibly the extra six residues at
the NH2 terminus of peptide 3 may conformationally mask
the COOH-terminus, the NH2-terminal region may be im-
munodominant, or antibodies directed to the NH2-terminal
region may interfere with neutralization by antibodies recog-
nizing the COOH-terminal sequences.
Nature of Neutralization Sites. The mechanism of neutral-
ization of infectivity by antibody remains obscure. Our data
and much previous evidence (19-22) implies that some anti-
bodies bind to virions but do not neutralize infectivity. In our
case, certain peptides specifically induced such antibodies,
which were recognized by their ability to quite significantly
reduce viral titers without ever abolishing infectivity, a be-
havior we interpret as due to aggregation of virions. Why
binding of antibody to some parts of the virion elicits neutral-
ization and binding to others does not is a puzzle that might
be clarified if the three-dimensional structure of the virion
were known. Neutralization appears to require binding of
multiple bivalent antibody molecules to the virion surface
(23, 24), suggesting a crosslinking stabilization effect, so that
the physical relationship of the 60 identical sites on the virion
surface may be an important parameter of neutralization.
The four VP1 sites that induce neutralizing antibodies appear
to be separated along the one-dimensional structure of the
polypeptide sequence but could come together to form a sin-
gle site when the polypeptide is folded up in the virion. X-ray
crystallography is most likely to illuminate this question (25).
The anti-peptide antisera do allow us to identify regions of
VP1 that are accessible to antibody and, therefore, opera-
tionally at the surface of the virion. The blackened and stip-
pled areas in Fig. 1 define surface regions, showing, as
would be expected, that the polypeptide is folded in a com-
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plicated configuration. A large percentage of the tested pep-
tides are at least partially exposed at the surface, consistent
with reports that VP1 is the most exposed of the three major
virion proteins (26, 27).
That two different species of animals both produced neu-
tralizing antibodies to the same set of determinants suggests
that it is the structure of the virion that determines the bio-
logical phenotype of the antisera, not the immune response
genetics of the inoculated animal. However, it may be signif-
icant that both species are insusceptible to poliovirus infec-
tion by virtue of lacking cell-surface receptors (28-30). Per-
haps primates or humans, in which poliovirus grows produc-
tively, might respond differently.
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